Abstract
Elevated metallothionein (MT) expression in ovarian cancers treated with cisplatin-based schemes represents an unfavorable prognostic index. MT expression is significantly higher in tumor samples obtained after chemotherapy. The present study aimed at examining MT expression in ovarian carcinoma cells sensitive (A2780) or resistant (A2780RCIS) against platinum drug treatment as well as examining effects of exposure to cisplatin on MT expression. Subcellular expression of MT was evaluated also in samples originating from 73 ovarian tumors. Cisplatin-resistant A2780RCIS cells were exposed to increasing cisplatin concentrations, and the subcellular expression of MT was determined by immunocytochemistry. The studies demonstrated that cisplatin-resistant A2780RCIS cells exposed to cisplatin typically manifested a nuclear MT expression. The study demonstrated also that exposure to cisplatin was paralleled by growing MT expression in cell nuclei. The nuclear expression of MT was also found to be specific for ovarian cancers of poor clinical outcome. No relationship could be demonstrated between cytoplasmic expression of MT and clinical variables. Nuclear MT expression is induced by cisplatin and seems to protect DNA in the cells from toxic effects of the drug.
Similar content being viewed by others
References
Apostolova MD, Chen S, Chakrabarti S, Cherian MG (2001) High-glucose-induced metallothionein expression in endothelial cells: An endothelin-mediated mechanism. Am J Physiol Cell Physiol 281:C899–C907
Apostolova MD, Cherian MG (2000) Delay of M-phase onset by aphidicolin can retain the nuclear localization of zinc and metallothionein in 3T3-L1 fibroblasts. J Cell Physiol 183:247–253
Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Karnel LH, Winchester DPSO (1993) National survey of ovarian carcinoma. 1. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629–1638
Cherian MG, Apostolova MD (2000) Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 46:347–356
Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, Lage H (2006) Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines. Int J Cancer 118:1699–1712
Hagrman D, Goodisman J, Dabrowiak JC, Souid AK (2003) Kinetic study on the relation of cisplatin with metallothionein. Drug Metab Dispos 31:916–923
Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Sem Surg Oncol 19:3–10
Kondo Y, Kuo SM, Watkins SC, Lazo JS (1995) Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55:474–477
Kowalski P, Surowiak P, Lage H (2005) Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Molec Ther 11:508–522
Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22:188–199
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
Siegsmund MJ, Marx C, Seeman O, Schummer B, Steidler A, Toktomambetova L, Kohrmann KU, Rassweiler J, Alken P (1999) Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 27:157–163
Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF (1998) The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559–565
Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M (2005) Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv 447:626–633
Takahashi Y, Ogra Y, Suzuki KT (2005) Nuclear trafficking of metallothionein requires oxidation of a cytosolic partner. J Cell Physiol 202:563–569
Wrigley E, Verpaget HW, Jayson GC, McGown AT (2000) Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 126:717–721
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Surowiak, P., Materna, V., Maciejczyk, A. et al. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450, 279–285 (2007). https://doi.org/10.1007/s00428-006-0362-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-006-0362-7